Genitourinary Syndrome of Menopause Genitourinary syndrome of Menopause (GSM), Autologous PRP, Vaginal Maturation index
Conditions
Interventions
The PRP (Platelet-Rich Plasma) product is derived from the patient herself. A blood sample of 10 ml is drawn and collected in a clotted blood tube. The sample is then centrifuged using a double centri
Experimental Biological/Vaccine
Sponsors
Research Fund, Faculty of Medicine, Thammasat University
Eligibility
Sex/Gender
Female
Age
45 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Postmenopausal women aged between 45 and 70 years 2. Diagnosed with Genitourinary Syndrome of Menopause (GSM) based on clinical symptoms (vaginal dryness, dyspareunia) 3. Low baseline Vaginal Maturation Index (VMI) (less than 50% superficial and intermediate cells) 4. Willing and able to provide informed consent through a comprehensive informed consent process
Exclusion criteria
Exclusion criteria: 1. Currently using estrogen in any form 2. History of radiation therapy or pelvic surgery affecting the urinary or reproductive systems 3. Present genital or urinary tract infection 4. Abnormal bleeding or platelet disorders 5. Contraindications to blood draw or injection
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Vaginal maturation index time of intervention, 1 month and 3 months after intervention use VMI scoring formula | — |
Secondary
| Measure | Time frame |
|---|---|
| Visual analog scale time of intervention, 1 month and 3 months post-intervention according to scale description ,Vulvovaginal symptoms questionnaire time of intervention, 1 month and 3 months post-intervention questionnaire interview ,Safety time of intervention, 1 month and 3 months post-invention adverse effects report,Feasibility After end of the intervention Retention rate and dropout rate | — |
Countries
Thailand
Contacts
Public ContactTewit Siridet
Thammasat university
Outcome results
None listed